Suven Life Sciences Achieves 100% Patient Enrollment for Phase-2B Ropanicant Trial

Suven Life Sciences has achieved a significant milestone by completing 100% patient enrollment for its Phase-2B trial of Ropanicant in Major Depressive Disorder (MDD), more than two months ahead of schedule. The clinical-stage biopharmaceutical company successfully enrolled 195 patients across 35 sites in the USA within six months of study initiation.

Trial Design and Enrollment Achievement

The Phase-2B study represents a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Ropanicant compared to placebo in patients with MDD. The trial measures improvements in depression symptoms using the Montgomery-Asberg Depression Rating Scale (MADRS) over a six-week treatment duration.

Trial Parameter:	Details
Study Phase:	Phase-2B
Drug Candidate:	Ropanicant (SUVN-911)
Indication:	Major Depressive Disorder (MDD)
Enrollment Target:	195 patients
Study Sites:	35 locations in USA
Study Duration:	Six weeks treatment
Enrollment Timeline:	Completed in less than 6 months

Timeline and Expected Results

With patient enrollment now complete, Suven Life Sciences expects the last patient out (LPO) by the end of February 2026. The company anticipates topline efficacy and safety results by May 2026. Safety data from the ongoing study continues to be monitored, with no significant concerns observed to date.

Management Commentary

Venkat Jasti, Chairman and Managing Director of Suven Life Sciences, expressed gratitude to patients, caregivers, investigators, and the clinical development team for their exceptional commitment in achieving this milestone rapidly. He emphasized that this collective progress moves the company closer to delivering new therapeutic options that can meaningfully improve patient lives.

Dr. Ramakrishna Nirogi, President and CSO, highlighted that reaching 100% patient enrollment approximately six months from study initiation reflects high interest from patients and physicians in a potential treatment option with a novel mechanism of action.

About Ropanicant

Ropanicant (SUVN-911) is a novel, selective nicotinic α4β2 receptor antagonist in development for MDD. The drug candidate has demonstrated strong efficacy in animal models of depression and may address key limitations of current treatments, including rapid onset of action, reduced sexual dysfunction, and enhanced cognitive function. The Phase-2a trial previously demonstrated a favorable safety profile and significant improvements in depressive symptoms as measured by the MADRS score.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.15%	-0.55%	-0.62%	-25.80%	+26.24%	+113.54%

Suven Life Sciences Limited , a prominent player in the pharmaceutical sector, has submitted its monitoring agency report for the quarter ended September 30, 2025, detailing the utilization of proceeds from its preferential issue of convertible warrants. The report, prepared by CRISIL Ratings Limited, confirms that the company has adhered to its stated objectives without any deviations.

Key Highlights

Issue Size: The total preferential issue amounts to Rs 85,764.02 lakh.
Funds Received: During the quarter, the company received 25% of the issue amount, totaling Rs 21,441.00 lakh.
Remaining Funds: The balance 75% (Rs 64,323.01 lakh) is expected to be received when warrant holders exercise their conversion options by December 2026.

Utilization of Proceeds

The company has allocated the funds across four primary categories:

Category	Amount (Rs in lakh)
Clinical development through overseas subsidiary	2,616.27
Drug discovery research	1,172.80
New R&D center infrastructure	92.98
General corporate purposes	1,542.08
Total Utilized	5,424.12

Unutilized Funds

As of September 30, 2025, Suven Life Sciences has Rs 25,298.59 lakh in unutilized proceeds. These funds have been strategically deployed in various mutual funds and money market instruments to ensure optimal returns while maintaining liquidity.

Investment Strategy

The company has invested the unutilized funds across multiple financial instruments:

Instrument	Amount Invested (Rs in lakh)	Market Value as of Sept 30, 2025 (Rs in lakh)
HDFC Money Market Fund	2,908.49	2,948.33
HDFC CRISIL-IBX Fin Services 3-6 Months Debt Index Fund	1,500.00	1,522.17
Nippon India Money Market Fund	4,110.72	4,167.67
Tata Money Market Fund	3,000.00	3,042.22
UTI Money Market Fund	3,000.00	3,041.53
ICICI Prudential Money Market Fund	3,253.66	3,298.17
Other Funds and Bank Accounts	7,525.72	7,604.66
Total	25,298.59	25,624.75

Future Outlook

Suven Life Sciences is expected to receive the remaining 75% of the issue amount as warrant holders exercise their conversion options. This influx of capital may further support the company's research and development initiatives, particularly in clinical development and drug discovery.

The company's strategic allocation of funds across various financial instruments demonstrates a balanced approach to fund management, aiming to maximize returns while maintaining the necessary liquidity for ongoing and future projects.

As Suven Life Sciences continues to utilize these funds in line with its stated objectives, investors and market watchers will likely monitor the company's progress in its clinical development and R&D efforts, which could potentially drive future growth and innovation in the pharmaceutical sector.